3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
3
Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Fulvestrant
125
Trastuzumab
114
Paclitaxel
113
Letrozole
108
pembrolizumab
79
pertuzumab
75
palbociclib
75
Capecitabine
72
Anastrozole
72
Cyclophosphamide
70
Carboplatin
67
abemaciclib
64
exemestane
63
Tamoxifen
63
ribociclib
60
trastuzumab deruxtecan
57
Surveys and Questionnaires
51
Specimen Handling
50
Radiotherapy
49
Docetaxel
49
Magnetic Resonance Spectroscopy
48
Blood Specimen Collection
40
olaparib
39
Standard of Care
36
Biopsy
33
sacituzumab govitecan
31
130-nm albumin-bound paclitaxel
31
Doxorubicin
30
Exercise
29
eribulin
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
sarilumab
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled